The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

News and commentary from the psychiatry world ...

With an expiration date still more than a year away, here's what the latest details reveal.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

Understood reports that artificial food dyes, like Red 40, may worsen ADHD symptoms in some children, prompting a phase-out ...

The FDA approved external trigeminal nerve stimulation (TNS) in 2019 as the first non-drug device for treating ADHD, ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...

A commonly used ADHD medication is being recalled nationwide after failing lab tests. The medication, lisdexamfetamine dimesylate capsules, is the generic form of Vyvanse, a stimulant that improves ...